Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of ZYPREXA and ZYPREXA VELOTAB in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ZYPREXA and ZYPREXA VELOTAB, as with all other anti-psychotics (including first generation anti-psychotics), provide a moderate Improvement in Actual Benefit (IAB III) in the treatment of schizophrenia. |
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
zYP3VpU4TJH5hgTV
